Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example

International Journal of Molecular Sciences

Volumn 11, Issue 11, 2010, Pages 4697-4714

  Liguori, Michael J ^a   Ditewig, Amy C ^a   Maddox, Jane F ^b   Luyendyk, James P ^b,e   Lehman Mckeeman, Lois D ^c   Nelson, David M ^d   Bhaskaran, Vasanthi M ^c   Waring, Jeffrey F ^a   Ganey, Patricia E ^b   Roth, Robert A ^b   Blomme, Eric A G ^a  

^a ABBOTT LABORATORIES   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Idiosyncratic hepatotoxicity; Inflammation; Liver; Rat; Transcriptomics

Indexed keywords

LIPOPOLYSACCHARIDE; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IDIOSYNCRATIC DRUG REACTION; INFLAMMATION; LIVER STRUCTURE; LIVER TOXICITY; NONHUMAN; RAT; SIGNAL TRANSDUCTION; TOXICITY TESTING; TRANSCRIPTOMICS;

IDIOSYNCRATIC HEPATOTOXICITY; INFLAMMATION; LIVER; RAT; TRANSCRIPTOMICS;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; FLUOROQUINOLONES; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; NAPHTHYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); RATTUS;

EID: 78650981874     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11114697     Document Type: Article

References (34)

1. Liguori, M.J.; Waring, J.F. Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions. Exp. Opin. Drug Metab. Toxicol. 2006, 2, 835-846.
2. Roth, R.A.; Ganey, P.E. Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J. Pharmacol. Exp. Ther. 2010, 332, 692-697.
3. Deng, X.; Stachlewitz, R.F.; Liguori, M.J.; Blomme, E.A.; Waring, J.F.; Luyendyk, J.P.; Maddox, J.F.; Ganey, P.E.; Roth, R.A. Modest inflammation enhances diclofenac hepatotoxicity in rats: Role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 2006, 319, 1191-1199.
4. Waring, J.F.; Liguori, M.J.; Luyendyk, J.P.; Maddox, J.F.; Ganey, P.E.; Stachlewitz, R.F.; North, C.; Blomme, E.A.; Roth, R.A. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 2006, 316, 1080-1087.
5. Luyendyk, J.P.; Maddox, J.F.; Cosma, G.N.; Ganey, P.E.; Cockerell, G.L.; Roth, R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 2003, 307, 9-16.
6. Buchweitz, J.P.; Ganey, P.E.; Bursian, S.J.; Roth, R.A. Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 2002, 300, 460-467.
7. Zou, W.; Beggs, K.M.; Sparkenbaugh, E.M.; Jones, A.D.; Younis, H.S.; Roth, R.A.; Ganey, P.E. Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J. Pharmacol. Exp. Ther. 2009, 331, 114-121.
8. Shaw, P.J.; Hopfensperger, M.J.; Ganey, P.E.; Roth, R.A. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol. Sci. 2007, 100, 259-266.
9. Stahlmann, R. Clinical toxicological aspects of fluoroquinolones. Toxicol. Lett.2002,127, 269-277.
10. Blomme, E.A.; Yang, Y.; Waring, J.F. Use of toxicogenomics to understand mechanisms of drug- induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 2009, 186, 22-31.
11. Shaw, P.J.; Ganey, P.E.; Roth, R.A. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J. Pharmacol. Exp. Ther. 2009, 330, 72-78.
12. Shaw, P.J.; Ditewig, A.C.; Waring, J.F.; Liguori, M.J.; Blomme, E.A.; Ganey, P.E.; Roth, R.A. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol. Sci. 2009, 107, 270-280.
13. De Castro, C.; Molinaro, A.; Lanzetta, R.; Silipo, A.; Parrilli, M. Lipopolysaccharide structures from Agrobacterium and Rhizobiaceae species. Carbohydr. Res. 2008, 343, 1924-1933.
14. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001, 104, 487-501.
15. Bradley, J.R. TNF-mediated inflammatory disease. J. Pathol. 2008, 214, 149-160.
16. Deng, X.; Luyendyk, J.P.; Ganey, P.E.; Roth, R.A. Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models. Pharmacol. Rev. 2009, 61, 262-282.
17. Shaw, P.J.; Beggs, K.M.; Sparkenbaugh, E.M.; Dugan, C.M.; Ganey, P.E.; Roth, R.A. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol. Sci. 2009, 111, 288-301.
18. Doyle, S.L.; O'Neill, L.A. Toll-like receptors: From the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 2006, 72, 1102-1113.
19. Mitchell, J.A.; Paul-Clark, M.J.; Clarke, G.W.; McMaster, S.K.; Cartwright, N. Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J. Endocrinol. 2007, 193, 323-330.
20. Rousseau, S.; Papoutsopoulou, M.; Symons, A.; Cook, D.; Lucocq, J.M.; Prescott, A.R.; O'Garra, A.; Ley, S.C.; Cohen, P. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J. Cell Sci. 2008, 121, 149-154.
21. Janssens, S.; Beyaert, R. Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 2003, 16, 637-646.
22. Kol, A.; Bourcier, T.; Lichtman, A.H.; Libby, P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 1999, 103, 571-577.
23. Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 2004, 199, 227-250.
24. Loegering, D.J.; Drake, J.R.; Banas, J.A.; McNealy, T.L.; Mc Arthur, D.G.; Webster, L.M.; Lennartz, M.R. Francisella tularensis LVS grown in macrophages has reduced ability to stimulate the secretion of inflammatory cytokines by macrophages in vitro. Microb. Pathog. 2006, 41, 218-225.
25. Ribot, W.J.; Panchal, R.G.; Brittingham, K.C.; Ruthel, G.; Kenny, T.A.; Lane, D.; Curry, B.; Hoover, T.A.; Friedlander, A.M.; Bavari, S. Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect. Immun. 2006, 74, 5029-5034.
26. Muriel, P. NF-kappaB in liver diseases: A target for drug therapy. J. Appl. Toxicol. 2009, 29, 91-100.
27. Xia, Z.P.; Chen, Z.J. TRAF2: A double-edged sword? Sci. STKE 2005, 2005, pe7.
28. Shaw, P.J.; Ganey, P.E.; Roth, R.A. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J. Pharmacol. Exp. Ther. 2009, 328, 62-68.
29. Adams, D.H.; Ju, C.; Ramaiah, S.K.; Uetrecht, J.; Jaeschke, H. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 2010, 115, 307-321.
30. Spriggs, D.; Imamura, K.; Rodriguez, C.; Horiguchi, J.; Kufe, D.W. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Natl. Acad. Sci. USA 1987, 84, 6563-6566.
31. Bader, T.; Nettesheim, P. Tumor necrosis factor-alpha modulates the expression of its p60 receptor and several cytokines in rat tracheal epithelial cells. J. Immunol. 1996, 157, 3089-3096.
32. Spriggs, D.R.; Sherman, M.L.; Imamura, K.; Mohri, M.; Rodriguez, C.; Robbins, G.; Kufe, D.W. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res. 1990, 50, 7101-7107.
33. Ganter, B.; Snyder, R.D.; Halbert, D.N.; Lee, M.D. Toxicogenomics in drug discovery and development: Mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. Pharmacogenomics 2006, 7, 1025-1044.
34. Luyendyk, J.P.; Lehman-McKeeman, L.D.; Nelson, D.M.; Bhaskaran, V.M.; Reilly, T.P.; Car, B.D.; Cantor, G.H.; Maddox, J.F.; Ganey, P.E.; Roth, R.A. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: Comparison with famotidine. Toxicol. Sci. 2006, 90, 569-585.